Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?

Antioxidants and Redox Signaling

Volumn 18, Issue 18, 2013, Pages 2392-2398

  Abdel Fatah, Tarek ^a   Arora, Arvind ^b   Gorguc, Ipek ^b   Abbotts, Rachel ^b   Beebeejaun, Sarah ^c   Storr, Sarah ^b   Mohan, Vivek ^b   Hawkes, Claire ^c   Soomro, Irshad ^c   Lobo, Dileep N ^c   Parsons, Simon L ^a   Madhusudan, Srinivasan ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; DNA; DNA GLYCOSYLTRANSFERASE; ENDONUCLEASE; FLAP ENDONUCLEASE 1; REACTIVE OXYGEN METABOLITE; SINGLE STRAND SELECTIVE MONOFUNCTIONAL URACIL DNA GLYCOSYLASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; DNA DAMAGE; DNA REPAIR; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION;

ADENOCARCINOMA; AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; FLAP ENDONUCLEASES; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REACTIVE OXYGEN SPECIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URACIL-DNA GLYCOSIDASE;

ATAXIA TELANGIECTASIA;

EID: 84878559099     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4873     Document Type: Article

References (10)

1. An Q, Robins P, Lindahl T, and Barnes DE. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosy-lase to reduce drug cytotoxicity. Cancer Res 67: 940-945, 2007.
2. Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
3. Chen BP, Li M, and Asaithamby A. New insights into the roles of ATM and DNA-PKcs in the cellular response to oxidative stress. Cancer Lett 2011 [Epub ahead of print]: DOI: 10.1016/j.canlet.2011.12.004.
4. Kang B, Guo RF, Tan XH, Zhao M, Tang ZB, and Lu YY. Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res 638: 17-25, 2008.
5. Kim YJ and Wilson DM, 3rd. Overview of base excision repair biochemistry. Curr Mol Pharmacol 5: 3-13.
6. Pelicano H, Carney D, and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004.
7. Seo Y and Kinsella TJ. Essential role of DNA base excision repair on survival in an acidic tumor microenvironment. Cancer Res 69: 7285-7293, 2009.
8. Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzie-nicka MZ, Qutob H, Seedhouse C, Laughton CA, Fischer PM, Patel PM, Wilson DM, 3rd, and Madhusudan S. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 2012 [Epub ahead of print]; DOI: 10.1002/ijc.27512.
9. Zheng L, Jia J, Finger LD, Guo Z, Zer C, and Shen B. Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res 39: 781-794.
10. Date of first submission to ARS Central, August 9, 2012; date of acceptance, August 16, 2012.